Assembly Biosciences (ASMB) News
NASDAQ: ASMBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
22.19-0.31 (-1.38%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ASMB news summary
We found 4 recent headlines mentioning Assembly Biosciences (ASMB): 0 in the past week and 4 in the past 30 days, most often from GlobeNewswire, Nasdaq. For price context, ASMB is down 1.38% at $22.19. The most recent story, "Assembly Biosciences, Inc. Reports Third Quarter 2026 Financial Results and Recent Updates", was published by Nasdaq on Nov 13, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Assembly Biosciences headlines
- Assembly Biosciences, Inc. Reports Third Quarter 2026 Financial Results and Recent UpdatesAssembly Biosciences, Inc. reported its financial results for the third quarter ended September 30, 2026. Cash, cash equivalents and marketable securities were $314.3 million as of September 30,…Nasdaq
- Assembly Biosciences Reports Third Quarter 2026 Financial Results and Recent Updates– Initiated Phase 2 clinical study of ABI-6250 in patients with chronic hepatitis delta virus infection –GlobeNewswire
- Assembly Biosciences to Participate in Upcoming Investor ConferencesSOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver…GlobeNewswire
- Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus– Phase 2 study will evaluate the safety, pharmacokinetics and antiviral activity of ABI-6250 in participants with chronic HDV infection – – Initial data from the Phase 2 study is expected in the…GlobeNewswire